```json
{
"content": [
{
"type": "faq",
"items": [
{
"Q": "What is the current market size?",
"A": "The respiratory distress syndrome market size was valued at USD 1.2 billion in 2023, driven by increasing preterm births and advancements in neonatal care technologies."
},
{
"Q": "What is the expected growth rate?",
"A": "The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising R&D investments and expanding healthcare infrastructure in emerging economies."
},
{
"Q": "What are the key growth drivers?",
"A": "Rising preterm birth rates, innovations in surfactant therapies, and growing awareness about neonatal respiratory care are the primary drivers for the respiratory distress syndrome market."
},
{
"Q": "What challenges exist in the market?",
"A": "High treatment costs, limited reimbursement coverage, and the lack of effective long-term therapies hinder the market growth for respiratory distress syndrome."
},
{
"Q": "Which regions lead the market?",
"A": "North America dominates the respiratory distress syndrome market due to advanced healthcare systems, followed by Europe and the Asia-Pacific region, which is growing rapidly."
},
{
"Q": "Who are the top companies?",
"A": "Leading players include Merck & Co., Johnson & Johnson, and Vertex Pharmaceuticals, which focus on developing surfactant-based and novel therapeutic solutions for RDS."
},
{
"Q": "What future opportunities exist?",
